SCHEMBL3102206

SCHEMBL3102206

CC(Oc1ccc2nc(NC(=O)NCCN3CCC(Cc4ccccc4)CC3)sc2c1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.46
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
MET P08581 8/20 0.42
CCR3 P51677 4/20 0.42
HTR2A P28223 1/20 0.42
KDR P35968 3/20 0.41
MAPK1 P28482 1/20 0.40
SRC P12931 2/20 0.40
KIT P10721 2/20 0.40
FGFR2 P21802 2/20 0.40
AXL P30530 2/20 0.40
FLT3 P36888 2/20 0.40
MST1R Q04912 2/20 0.40
AURKA O14965 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
IGF1R P08069 1/20 0.40
EPHA2 P29317 1/20 0.40
LTK P29376 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109350 0.91 ABL1 (0.48) ABL1METKDRSRC
SCHEMBL3102006 0.90 CHRM4 (0.47) MET
SCHEMBL3102959 0.88 MET (0.51) ABL1METKDRSRCKIT
SCHEMBL3104505 0.88 ABL1 (0.53) ABL1METKDRSRCKIT
SCHEMBL3114877 0.88 MET (0.50) ABL1METKDRSRCKIT
SCHEMBL3650560 0.87 ABL1 (0.46) ABL1METKDRSRCKIT
SCHEMBL3097744 0.86 MET (0.55) ABL1MET
SCHEMBL3094120 0.86 MET (0.55) ABL1MET
SCHEMBL3788533 0.86 ABL1 (0.54) ABL1METKDRSRCKIT
SCHEMBL3093085 0.86 MET (0.55) ABL1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 ABL1 4/4885SLC6A2 1559/4885SLC6A3 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.